These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 34908180

  • 1. Complex survival trial design by the product integration method.
    Tang Y.
    Stat Med; 2022 Feb 20; 41(4):798-814. PubMed ID: 34908180
    [Abstract] [Full Text] [Related]

  • 2. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y.
    Stat Methods Med Res; 2021 May 20; 30(5):1211-1234. PubMed ID: 33819109
    [Abstract] [Full Text] [Related]

  • 3. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P, Ye J, Anderson KM, Roychoudhury S, Rubin EH, Halabi S, Chappell RJ.
    JAMA Oncol; 2022 Sep 01; 8(9):1294-1300. PubMed ID: 35862037
    [Abstract] [Full Text] [Related]

  • 4. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ, Liu GF, Wu WC.
    BMC Med Res Methodol; 2020 Aug 27; 20(1):218. PubMed ID: 32854619
    [Abstract] [Full Text] [Related]

  • 5. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z, Zhang Q, Xue A, Whitmore J.
    Pharm Stat; 2024 Aug 27; 23(3):325-338. PubMed ID: 38152873
    [Abstract] [Full Text] [Related]

  • 6. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J, Li Y, Zhu L.
    J Biopharm Stat; 2024 Jan 02; 34(1):1-15. PubMed ID: 36740768
    [Abstract] [Full Text] [Related]

  • 7. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
    Jiménez JL.
    J Appl Stat; 2022 Jan 02; 49(2):466-484. PubMed ID: 35707213
    [Abstract] [Full Text] [Related]

  • 8. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S, Chu C, Rong A.
    Pharm Stat; 2018 Sep 02; 17(5):541-554. PubMed ID: 30058101
    [Abstract] [Full Text] [Related]

  • 9. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X, Wu J.
    Pharm Stat; 2017 Jan 02; 16(1):87-94. PubMed ID: 27860138
    [Abstract] [Full Text] [Related]

  • 10. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
    Yu C, Huang X, Nian H, He P.
    Pharm Stat; 2021 May 02; 20(3):528-550. PubMed ID: 33427400
    [Abstract] [Full Text] [Related]

  • 11. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J, Wei J.
    Stat Med; 2022 Feb 20; 41(4):786-797. PubMed ID: 34779534
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A, Therneau T, Le-Rademacher J.
    Clin Trials; 2020 Jun 20; 17(3):285-294. PubMed ID: 32063031
    [Abstract] [Full Text] [Related]

  • 14. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C, Liu S, Rong A.
    Pharm Stat; 2020 Jul 20; 19(4):358-369. PubMed ID: 31930622
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
    Horiguchi M, Tian L, Uno H.
    Stat Med; 2023 Apr 15; 42(8):1139-1155. PubMed ID: 36653933
    [Abstract] [Full Text] [Related]

  • 18. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P, Ristl R, König F, Posch M, Jennison C, Götte H, Schüler A, Mehta C.
    Biom J; 2022 Feb 15; 64(2):343-360. PubMed ID: 34935177
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H, He J.
    Biom J; 2023 Apr 15; 65(4):e2100403. PubMed ID: 36789566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.